TIDMAVO
RNS Number : 5997C
Advanced Oncotherapy PLC
11 February 2020
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the
publication of this announcement via a Regulatory Information
Service, this inside information is now considered to be in the
public domain.
11 February 2020
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Advanced Oncotherapy partners with The London Clinic, a
pioneering cancer treatment centre, to operate Harley Street proton
therapy facility
Advanced Oncotherapy will lease part of The London Clinic's
premises to install a second treatment room
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment, is
pleased to announce a memorandum of understanding ("MoU") with The
London Clinic, the UK's leading private independent hospital, to
operate Advanced Oncotherapy's first commercial LIGHT facility on
Harley Street in London.
The London Clinic has selected Advanced Oncotherapy as its
partner for proton therapy not only because LIGHT's reduced volume
and modularity allow for implementation in existing clinical sites
and densely populated areas where space is scarce, but also because
Advanced Oncotherapy's LIGHT system has been designed to generate a
much smaller beam and, as such, is able to deliver more precise
treatment due to the electronically-controllable energy modulation
of the proton beams.
Under the terms of the MoU, it is intended that Advanced
Oncotherapy will provide the LIGHT proton accelerator and treatment
room equipment and The London Clinic will source and manage
staffing, governance and other services necessary for the clinical
operation of the facility. Advanced Oncotherapy and The London
Clinic will receive a share of the profit generated by the centre.
The full terms of the partnership between Advanced Oncotherapy and
The London Clinic remain confidential.
The London Clinic, one of the UK's largest private charitable
hospitals, has a pioneering cancer treatment centre in its Duchess
of Devonshire wing, which is at the forefront of advancing
healthcare. Current innovation includes offering cancer patients
advanced diagnostic scanning, adaptive radiotherapy for bladder
cancer and the use of hydrogel spacers to minimise the side effects
of prostate cancer radiation therapy. The London Clinic, as part of
its charitable purpose, also offers free of charge survivorship
programmes for cancer patients.
Al Russell, Chief Executive Officer of The London Clinic,
commented:
"Proton beam therapy is a very exciting new treatment but access
has been limited due to the costs and size of equipment. Until now.
Advanced Oncotherapy's LIGHT system reduces size and cost, while
providing the same high success rate for patients. We're excited to
be the first hospital in London to offer this new treatment. The
new service will adjoin our main site on Harley Street, and enable
The London Clinic to help even more patients fight and survive
cancer while furthering our aim of advancing healthcare."
Nicolas Serandour, Chief Executive Officer of Advanced
Oncotherapy, commented:
"We are delighted to announce that The London Clinic will now
operate our Harley Street LIGHT facility, the agreement with Circle
Health having lapsed. The site is expected to allow us to treat a
wide group of patients and help drive further awareness to proton
beam therapy for the treatment of cancer. The London Clinic is one
of the leading private cancer treatment hospitals in the UK and its
decision to select our LIGHT system for proton beam therapy is a
significant validation of our technology and capabilities. The
proposed profit-sharing agreement with The London Clinic ensures
that Advanced Oncotherapy retains an interest in the future success
of the facility."
- ENDS -
FOR MORE INFORMATION AND MEDIA INTERVIEWS, CONTACT:
Advanced Oncotherapy plc www.avoplc.com
Dr. Michael Sinclair, Executive Tel: +44 (0) 20 3617 8728
Chairman
Nicolas Serandour, CEO
Allenby Capital Limited (Nominated
Adviser & Broker)
Nick Athanas / Liz Kirchner / Tel: +44 (0) 20 7601 6100
Nicholas Chambers
FTI Consulting (Financial PR & advancedoncotherapy@fticonsulting.com
IR)
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
The London Clinic www.thelondonclinic.co.uk
Neil Wilkins, Head of Communications Tel: +44 (0) 7704 53 66 33
n.wilkins@thelondonclinic.co.uk
Notes for Editors
About the London Clinic www.thelondonclinic.co.uk
The London Clinic is an independent, charitable hospital in
Harley Street, the heart of London's medical district. As a
pioneering hospital, The London Clinic's cutting-edge technologies
and world-renowned consultants attract thousands of patients every
year from global destinations. Our 600 consultants specialise in
cancer care, digestive diseases, orthopaedics (including hips,
knees, shoulders and fingers with on-site physiotherapy
rehabilitation), neurology, cosmetic surgery, liver services,
gastroenterology, urology, endoscopy, diabetes, haematology and
endocrinology.
About Advanced Oncotherapy plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRQFLBFBLLLBBL
(END) Dow Jones Newswires
February 11, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Advanced Oncotherapy (LSE:AVO)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Advanced Oncotherapy (LSE:AVO)
Storico
Da Apr 2023 a Apr 2024